Kura Oncology Toekomstige groei

Future criteriumcontroles 2/6

Kura Oncology zal naar verwachting groeien in winst en omzet met respectievelijk 26.5% en 65.6% per jaar. De winst per aandeel zal naar verwachting groeien met 29.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -59.9% zijn.

Belangrijke informatie

26.5%

Groei van de winst

29.8%

Groei van de winst per aandeel

Biotechs winstgroei	36.5%
Inkomstengroei	65.6%
Toekomstig rendement op eigen vermogen	-59.9%
Dekking van analisten	Good
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:KUR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	99	-206	-189	-201	12
12/31/2025	9	-239	-197	-203	14
12/31/2024	N/A	-212	-168	-185	13
6/30/2024	N/A	-182	-155	-155	N/A
3/31/2024	N/A	-168	-138	-138	N/A
12/31/2023	N/A	-153	-125	-125	N/A
9/30/2023	N/A	-143	-117	-117	N/A
6/30/2023	N/A	-140	-110	-109	N/A
3/31/2023	N/A	-137	-114	-114	N/A
12/31/2022	N/A	-136	-111	-110	N/A
9/30/2022	N/A	-135	-108	-107	N/A
6/30/2022	N/A	-133	-112	-110	N/A
3/31/2022	N/A	-132	-109	-108	N/A
12/31/2021	N/A	-130	-106	-105	N/A
9/30/2021	N/A	-124	-101	-99	N/A
6/30/2021	N/A	-114	-93	-92	N/A
3/31/2021	N/A	-101	-80	-79	N/A
12/31/2020	N/A	-90	-72	-70	N/A
9/30/2020	N/A	-81	-67	-65	N/A
6/30/2020	N/A	-74	-62	-61	N/A
3/31/2020	N/A	-68	-61	-60	N/A
12/31/2019	N/A	-63	-55	-55	N/A
9/30/2019	N/A	-61	-51	-51	N/A
6/30/2019	N/A	-60	-52	-52	N/A
3/31/2019	N/A	-60	-50	-50	N/A
12/31/2018	N/A	-60	-49	-49	N/A
9/30/2018	N/A	-55	-46	-46	N/A
6/30/2018	N/A	-49	-39	-39	N/A
3/31/2018	N/A	-43	N/A	-33	N/A
12/31/2017	N/A	-35	N/A	-28	N/A
9/30/2017	N/A	-32	N/A	-28	N/A
6/30/2017	N/A	-30	N/A	-27	N/A
3/31/2017	N/A	-28	N/A	-27	N/A
12/31/2016	N/A	-28	N/A	-25	N/A
9/30/2016	N/A	-27	N/A	-24	N/A
6/30/2016	N/A	-26	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-21	N/A
12/31/2015	N/A	-23	N/A	-18	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat KUR de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat KUR de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat KUR de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van KUR ( 65.6% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.6% per jaar).

Hoge groei-inkomsten: De omzet van KUR ( 65.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat KUR binnen 3 jaar verliesgevend zal zijn.

Kura Oncology Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

New minor risk - Share price stability

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Now 21% undervalued

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

New major risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

New 90-day low: €22.00

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: €24.40

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting

New 90-day high: €29.40

Kura Oncology, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Kura Oncology, Inc. Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Ka Inhibitor in Head and Neck Squamous Cell Carcinoma

New 90-day high: €26.40

Kura Oncology, Inc. to Report Q1, 2020 Results on May 04, 2020

New 90-day high: €24.80

New 90-day high - €18.50

New 90-day high - €17.50

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven